GPD1 modulators(glycerol-3-phosphate dehydrogenase 1 modulators), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators)

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseOther Diseases+ [8]

Active Indication

Differentiated Thyroid Gland CarcinomaDepressive DisorderHIV Infections+ [7]

Inactive Indication

Diabetes Mellitus, Type 2Ischemic stroke

Originator Organization

Elcelyx Therapeutics, Inc.

Active Organization

Baylor College of Medicine

University of MinnesotaMedical Research Agency

+ [3]

Inactive Organization

Anji Pharmaceuticals, Inc.

Elcelyx Therapeutics, Inc.

The Medical University of South Carolina

+ [2]

License Organization

Anji Pharmaceuticals (Shanghai) Co., Ltd.

Emory University

Elcelyx Therapeutics, Inc.

+ [3]

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC4H11N5

InChIKeyXZWYZXLIPXDOLR-UHFFFAOYSA-N

CAS Registry657-24-9

464

Clinical Trials associated with Metformin

NCT07007221

/ Not yet recruitingPhase 2IIT

Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV

Depression in HIV occurs commonly and causes poor HIV outcomes with public health implications.
Depression prevalence in HIV-infected persons is estimated at 26% compared to 5% in the general population. Adherence to antiretroviral medication is a life-saving treatment in HIV, but depression can reduce engagement in care and adherence to medication. Depression is also associated with poorer levels of viral suppression and even mortality. Overall, those with depression and HIV are less likely to return to health and remain more likely to transmit the virus. therefore, treatment of HIV is essential to prevention; lower engagement in and adherence to HIV treatment due to depression puts others at risk. This is a 3 part trial, an initial pilot, a placebo controlled pilot, and a full trial.
Part 1. Dose response, Tolerability/Acceptability of Metformin for Depression in people with HIV: To do Initial assessment of metformin for depression in people with HIV we will perform a randomized, double blind, 2-arm, 12 week randomized controlled trial to assess feasibility and acceptability of metformin for depression. We will test two doses of metformin 1000 mg daily versus 1500 mg daily.
Part 2. Preliminary Efficacy Trial of Metformin for Depression in People with HIV: This will be a two-arm, double-blind trial of metformin versus placebo in people with HIV and depression. We will randomize individuals 1:1 to metformin or placebo. Will then collect blood and rectal swabs for preliminary assessments of the mechanism of action for metformin in people with HIV and depression.
Part 3. Full efficacy factorial trial of metformin for depression and comparison/interaction with fluoxetine in people living with HIV: To assess metformin and fluoxetine as efficacious treatments for depression in people with HIV, we will conduct a 4-arm, 12-week, mechanistic, double-blinded, randomized controlled treatment trial (RCT) with an assessment of inflammation and the gut microbiome. Participants (n=400) will be HIV- positive patients on ART with comorbid depression receiving care at one of two Ugandan clinics. In addition, we will use the NIMH Research Domain Criteria (RDoC) of Acute Threat and loss under Negative Valence using biomarkers and self-reported tools.

Start Date01 Jan 2026

Sponsor / Collaborator

University of Minnesota

TCTR20240817009

/ Not yet recruitingPhase 1

A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin 50/1000 mg Film-coated Tablets and Reference Product (GALVUS MET (50 MG/1000 MG)) in Healthy Thai Volunteers under Fed Conditions

Start Date06 Feb 2025

Sponsor / Collaborator-

IRCT20220111053692N19

/ CompletedNot Applicable

Bioequivalence study of Metformin ER ??? mg Tablet (Tehran chemie) versus Glucophage® XR ??? mg (Merck-Brand) Tablet after single oral dosing in healthy volunteers

Start Date30 Dec 2024

Sponsor / Collaborator

Tehran Chemie Pharmaceutical Co.

100 Clinical Results associated with Metformin

100 Translational Medicine associated with Metformin

100 Patents (Medical) associated with Metformin

43,996

Literatures (Medical) associated with Metformin

01 Jan 2026·BIOMATERIALS

A poly(lipoic acid)-based elastomer adhesive with synergistic activity of microenvironment regulation and peripheral neuropathy repair facilitates infectious diabetic wound healing

Article

Author: Fu, Feng ; Shao, Jiaxing ; Cui, Chunyan ; Yang, Rong ; Qi, Ying ; Zhang, Qian ; Wang, Jingjing ; Chen, Yueyang ; Liu, Wenguang ; Luo, Zhen ; Song, Haotian ; Sun, Hongtao

Diabetic wounds are notorious for their difficulty in healing and high recurrence rate, due to their harsh inflammatory microenvironment and the peripheral neuropathy caused by a hyperglycemic condition. However, current research often overlooks the impact of diabetic peripheral neuropathy on hindering wound healing. Here, we develop an adhesive elastomeric wound dressing by combining the natural active molecule lipoic acid (LA) with the clinically applied hypoglycemic drug metformin (Met), integrating the characteristics of remodeling the wound microenvironment and restoring peripheral nerve function, while stabilizing polyLA through the formation of strong salt bridge hydrogen bonds between guanidyl and carboxyl. The surface of the elastomeric dressing rich in adhesive carboxyl groups can achieve effective sealing protection for diabetic wounds by forming multiple hydrogen bonds or electrostatic interactions with the tissues, thereby resisting harmful bacterial invasion. The sustained targeted release of LA and Met at the wound site can effectively reduce local oxidative stress, increase collagen deposition and angiogenesis, and significantly upregulate neuroendocrine chemicals and nerve fiber markers, promoting the recovery of peripheral nerves around the lesion. In the diabetic infection model in rats, the polyLA-Met patch shows a significantly superior wound healing effect compared to the commercial 3M dressing.

31 Dec 2025·Gut Microbes

Microbial succinate promotes the response to metformin by upregulating secretory immunoglobulin a in intestinal immunity

Article

Author: Liu, Bing ; Wang, Aiting ; Zhang, Yu ; Qin, Jia’an ; Yan, Dan ; Yao, Chengcheng ; Yuan, Mingxia ; Zhao, Wei ; Zhang, Ying ; Long, Jianglan

Metformin is the first-line pharmacotherapy for type 2 diabetes mellitus; however, many patients respond poorly to this drug in clinical practice. The potential involvement of microbiota-mediated intestinal immunity and related signals in metformin responsiveness has not been previously investigated. In this study, we successfully constructed a humanized mouse model by fecal transplantation of the gut microbiota from clinical metformin-treated - responders and non-responders, and reproduced the difference in clinical phenotypes of responsiveness to metformin. The abundance of Bacteroides thetaiotaomicron, considered a representative differential bacterium of metformin responsiveness, and the level of secretory immunoglobulin A (SIgA) in intestinal immunity increased significantly in responder recipient mice following metformin treatment. In contrast, no significant alterations in B. thetaiotaomicron and SIgA were observed in non-responder recipient mice. The study of IgA^-/- mice confirmed that downregulated expression or deficiency of SIgA resulted in non-response to metformin, meaning that metformin was unable to improve dysfunctional glucose metabolism and reduce intestinal and adipose tissue inflammation, ultimately leading to systemic insulin resistance. Furthermore, supplementation with succinate, a microbial product of B. thetaiotaomicron, potentially reversed the non-response to metformin by inducing the production of SIgA. In conclusion, we demonstrated that upregulated SIgA, which could be regulated by succinate, was functionally involved in metformin response through its influence on immune cell-mediated inflammation and insulin resistance. Conversely, an inability to regulate SIgA may result in a lack of response to metformin.

31 Dec 2025·ANNALS OF MEDICINE

Improvement of endocrine and metabolic conditions in patients with polycystic ovary syndrome through acupuncture and its combined therapies: a systematic review and meta-analysis

Review

Author: Hu, Jinqun ; Yang, Jie ; Kong, Fanjing ; Wu, Tianyu ; Liu, Yu ; Liu, Yiwei ; Chen, Jiao

BACKGROUND:

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder among women of reproductive age that significantly impacts their reproductive health. Acupuncture and its combined therapies may have beneficial effects on the endocrine and metabolic states of women with PCOS. This systematic review and meta-analysis evaluated the treatment effects and potential mechanisms of acupuncture and its combined therapies compared to oral metformin in treating PCOS patients.

METHODS:

The evaluation focused on three sets of outcomes: hormonal indicators, metabolic indicators, and body weight indicators. Studies that involved additional therapies beyond the specified interventions or included patients with other diseases were excluded. Additionally, data mining methods were used, including frequency statistics to analyze the frequency of acupuncture points and the meridians involved, and the Apriori algorithm to perform association rule analysis for the most effective interventions.

RESULTS:

The study included 46 articles (51 studies) involving six interventions: acupuncture combined with metformin, acupuncture treatment, acupuncture with Chinese herbal medicine and metformin, acupuncture with Chinese herbal medicine, acupuncture combined with cupping, and auricular acupuncture combined with metformin showed significant improvements in all evaluated indicators. Data mining revealed the Stomach meridian of foot yangming was the most frequently used, and the most commonly used combination of points included CV4, SP6, and ST36.

CONCLUSIONS:

This study suggests that acupuncture and its combined therapies may benefit PCOS. However, risk of bias and heterogeneity observed were noted. Future high-quality, rigorously designed randomized controlled trials are needed to confirm these findings and provide stronger clinical recommendations for acupuncture in PCOS treatment.

105

News (Medical) associated with Metformin

26 Jun 2025

·pharma.economictimes.indiatimes.com

Haffkine to quiz 2 pharmaceutical firms for selling it ‘blacklisted’ medicines for government hospitals in Maharashtra

Mumbai: Haffkine Bio-Pharmaceuticals procurement cell will be seeking explanations from two pharmaceutical firms after it came to light that medicines ordered for govt hospitals across the state in Feb had been declared "not of standard quality" and blacklisted by Employees' State Insurance Corporation (ESIC) just two months earlier. In Dec, ESIC issued a circular blacklisting specific drugs from seven pharmaceutical companies, citing test results that found these medicines to be of substandard quality and directing that no further orders be placed with them. However, Haffkine Bio-Pharmaceuticals placed large supply orders with two of the listed firms. This resulted in the procurement of nearly 21.9 lakh vials of Pantoprazole 40mg/10ml injection worth Rs 2.5 crore from Galpha Laboratories Ltd, and 88,650 tablets of Vildagliptin 50mg, along with Metformin Hydrochloride 1000mg worth nearly Rs 12.6 lakh, from Bajaj Healthcare Ltd. Pantoprazole is used to treat acid-related stomach issues such as ulcers and acid reflux, while Vildagliptin with Metformin is prescribed to manage type 2 diabetes by controlling blood sugar levels. Although Haffkine is no longer the primary authority for medicine procurement, it was granted permission to utilise the remaining Rs 131.6 crore to restock medicines at state-run hospitals through a Govt Resolution (GR). "The procurement process must be based on ESIC rate contracts as received on the e-Aushadhi platform," the GR stated. A senior official at the procurement cell confirmed that they are looking into the matter. "We have been orally informed by ESIC that the issue pertained to specific batches. Nevertheless, we have sought written responses from the companies as well as from ESIC. These will be submitted to higher authorities, and payments to the companies will be withheld until a reasonable explanation is provided," the official said, but did not provide the amount of payments to be withheld. Abhay Pandey, of the All Food and Drug Licence Holders Foundation, who flagged the issue with medical education department officials, alleged that the existing rate contract was arbitrarily selected by Haffkine without verifying the blacklisting status of the companies or conducting additional tests on the medicines. Haffkine officials did not respond when asked whether random sampling of the procured products was conducted in accordance with the GR. Dr Shashi Kolnoorkar, state ESIC director (Medical), said the blacklisting order came from the Delhi headquarters and that appropriate action had been taken at the time. When asked whether the blacklisting applied to specific batches or constituted a complete ban on the medicines in question, he referred the query to the ESIC head office. Attempts were made to reach Dr Neeta Garbiyal, deputy medical commissioner at the ESIC head office, who had signed the blacklist circular, but she was unavailable for comment. By Eshan Kalyanikar ,

NDA

16 Jun 2025

·www.einpresswire.com

GenBio Addresses Maintaining Glucose Homeostasis

Hormonal and neural regulatory mechanisms that maintain blood glucose levels within a very narrow range Science is fun. Science is curiosity. We all have natural curiosity. Science is a process of investigating. It's posing questions and coming up with a method. It's delving in.” — Sally Ride ALISO VIEJO, CA, UNITED STATES, June 16, 2025 / EINPresswire.com / -- Glucose from a diet is the major energy source for humans and other mammals. Blood glucose concentrations increase rapidly after food intake and then decline as glucose is used or stored. Since nutrient intake is irregular but energy requirement is continuous, the body needs to store glucose, usually as glycogen, mainly in the muscles and liver. Two peptides produced by the pancreas, insulin and glucagon, control glucose storage by enhancing glucose uptake and glycogen breakdown, respectively. Persistent high blood glucose concentrations result from diminished insulin production as in type 1 diabetes or insulin resistance, a decreased cellular response to insulin as in type 2 diabetes . Type 2 diabetes is a chronic disease defined by hyperglycemia leading to microvascular and macrovascular damage. The prevalence of diabetes has been increasing globally since 1990, attributed to living environments and lifestyle leading to poorer nutrition and increased sedentary behaviour. The International Diabetes Federation estimates that 11.1% of the world’s adult population aged 20-79 years, around 452 million people, is living with diabetes, with 4 in 10 of these people unaware that they have the disease. Diabetes is more prevalent in people aged 65 years and older, including 122 million of this population of 652 million, or around 19%; further, prediabetes affects 48% of the 26 million older adults in the USA. The risk to these patients is increased by multiple comorbidities, increased incidence of hypoglycemia, increased dependence on care and worsening frailty. Cardiovascular disease remains the leading cause of death in type 2 diabetics, even though a marked decrease in all-cause mortality of 30–35% in diabetics in the USA and England has been related to decreases in mortality from cardiovascular disease. Cancer rates have remained unchanged in diabetes patients, but this is now an increased percentage of deaths while mortality rates from dementia and liver disease have increased. Lifestyle modifications, including nutrition and exercise, are the foundation for the management of type 2 diabetes. Drug treatment of diabetes now includes metformin, which lowers liver production of glucose, sulphonylureas such as glyburide, which stimulate insulin production, thiazolidinediones such as pioglitazone which increase glucose uptake into tissues, prompting insulin secretion and decreasing appetite with glucagon-like peptide-1 receptor agonists, including semiglutide, combined glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists such as tirzepatide and preventing the reabsorption of glucose in the kidneys by sodium-glucose cotransporter-2 inhibitors such as dapagliflozin and empagliflozin. Research is continuing, so potential clinical use of adiponectin and fibroblast growth factor 21 could allow personalized approaches to lower blood glucose concentrations. Healthy eating plans are essential for long-term control of diabetes. Preclinical trials with anthocyanin-containing foods have shown regulation of blood glucose concentrations, improved gut microbiota, reduced insulin resistance and inflammation, and changed adipocyte function. Large prospective cohort trials in people in the USA have shown an inverse relationship between a healthy plant-based diet and the risk of developing diabetes. Dietary anthocyanin intake was linked to a 15% lower incidence of type 2 diabetes in 8 cohort studies involving 394,913 participants. In a summary of 18 human trials in type 2 diabetes from the last 5 years, anthocyanins reduced blood glucose and HbA1c concentrations and improved insulin secretion and resistance, especially in at-risk groups. Further, diets containing polyphenols such as anthocyanins may reduce the risk of developing diabetes. The incidence of type 2 diabetes decreased by 5% when the intake of anthocyanins increased by 7.5 mg/day. As examples, plums such as the Queen Garnet, Illawarra and Davidson’s varieties may contain 250-500 mg anthocyanins per 100g fruit. Other important dietary sources of anthocyanins include raspberries, bilberries, chokeberries, mulberries, and saskatoon berries. These clinical investigations support the preclinical studies that anthocyanins simultaneously affect many targets associated with type 2 diabetes. These studies reinforce that improving nutritional status in people with diabetes by adding anthocyanin-containing fruit to current treatment regimens is likely to improve clinical outcomes. Nutrition, exercise, and treatment with antidiabetic medications remain the key approaches to the treatment of type 2 diabetes. Todd D. Sonoga GenBio Inc. +1 949-705-8021 email us here Visit us on social media: LinkedIn Facebook X GenBio Inc Elevator Pitch Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

16 Jun 2025

·www.einpresswire.com

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions

– Hengrui to present six abstracts highlighting clinical progress of GLP-1/GIP dual receptor agonist HRS9531 (KAI-9531) and GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes and obesity – JIANGSU, China and BOSTON, June 16, 2025 (GLOBE NEWSWIRE) -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today announced the presentation of six abstracts at the 85th Scientific Sessions of the American Diabetes Association (ADA), taking place June 20-23, 2025, in Chicago, IL. The presentations will highlight the breadth of the companies’ metabolic disease portfolio, including data from several clinical-stage injectable and oral therapies. Data presented will cover results from clinical trials sponsored and conducted by Hengrui for an injectable GLP-1/GIP receptor dual agonist HRS9531 (in development as KAI-9531 outside of Greater China), an oral small molecule GLP-1 receptor agonist HRS-7535 (KAI-7535), and an oral formulation of HRS9531 (KAI-9531). The following abstracts were submitted by Hengrui and accepted for presentation: HRS9531 Oral presentation: Friday, June 20, 5:45-6:00 p.m. CT Phase 2 clinical trial of HRS9531 in participants with type 2 diabetes up to 32 weeks Abstract 126-OR: Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks Posters: Sunday, June 22, 12:30-1:30 p.m. CT Phase 1 clinical trial of HRS9531 (oral peptide) in healthy participants Abstract 797-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants: A Phase 1 Study Phase 2 clinical trial of HRS9531 in adults with obesity without diabetes up to 52 weeks Abstract 853-P: Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes: Up to 52-Week Treatment Phase 2 clinical trial of HRS9531 high dose (8 mg) in adults with obesity or overweight without diabetes Abstract 874-P: Efficacy and Safety of a Novel Dual GLP-1/GLP Receptor Agonist in Chinese Overweight or Obese Adults without Diabetes HRS-7535 Posters: Sunday, June 22, 12:30-1:30 p.m. CT Phase 2 clinical trial of HRS-7535 in adults with type 2 diabetes Abstract 837-P: Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin Phase 2 clinical trial of HRS-7535 in adults with obesity without diabetes Abstract 865-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA in Chinese Obese Adults without Diabetes All abstracts will be published online in the journal Diabetes ® and presentations will be accessible on the Scientific Publications section of the Kailera website following the congress. Additional information can be found on the ADA website . About Hengrui Pharma Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. With a global R&D team that includes 14 R&D centers and more than 5,500 professionals, Hengrui Pharma’s therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. To date, Hengrui has commercialized 23 new molecular entity drugs and 4 other innovative drugs in China. Founded in 1970 with the core principle of putting patients first, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. About Kailera Therapeutics Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that has demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit www.kailera.com and follow us on LinkedIn and X . Contact Information for Hengrui Pharma DGA Group hengrui@dgagroup.com Contact Information for Kailera Maura Gavaghan Vice President, Corporate Communications and Investor Relations maura.gavaghan@kailera.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Phase 2Clinical ResultPhase 1

100 Deals associated with Metformin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Metformin	A10BA02	DB00331

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Differentiated Thyroid Gland Carcinoma	Phase 3	Poland	Medical Research Agency	01 Nov 2022
Ischemic stroke	Phase 3	United States	The Medical University of South Carolina	01 Oct 2008
Diabetes Mellitus, Type 2	Phase 3	United States	National Institute of Diabetes & Digestive & Kidney Diseases	01 May 2004
Depressive Disorder	Phase 2	-	University of Minnesota	01 Jan 2026
HIV Infections	Phase 2	-	University of Minnesota	01 Jan 2026
Monoclonal Gammopathy of Undetermined Significance	Phase 2	United States	Dana-Farber Cancer Institute, Inc.	27 Apr 2021
Plasma Cell Leukemia	Phase 2	United States	Dana-Farber Cancer Institute, Inc.	27 Apr 2021
Smoldering Multiple Myeloma	Phase 2	United States	Dana-Farber Cancer Institute, Inc.	27 Apr 2021
COVID-19	Clinical	United States	University of Minnesota	18 Aug 2022
Osteoarthritis	Preclinical	China	North China University of Science & Technology	01 Aug 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02946996 (CTgov)	Phase 2	Prostatic Cancer \| Metastatic Prostate Carcinoma \| Adenocarcinoma of prostate	41	Metformin (Metformin Only)	mpdilgkcda(sekvmcucoo) = oiewijbxjq odiycwayye (jaacystgpv, zjbawiboef - zhrqxypbpd) View more	-	03 Feb 2025
				OPC (OPC Only)	mpdilgkcda(sekvmcucoo) = ggmknjqsci odiycwayye (jaacystgpv, egjbrdlhvc - pelikjvuon) View more
WCLC2024 Manual	Not Applicable	Non-Small Cell Lung Cancer	480	Metformin (Overweight patients)	nlhdzokiok(hujiqfxdvb): HR = 0.68 (95% CI, 0.457 - 1.011), P-Value = 0.057 View more	Positive	08 Sep 2024
				Metformin (Non-overweight patients)
NCT01107717 (EDICT \| EDICT study, CTgov)	Phase 4	Diabetes Mellitus, Type 2	318	exenatide+pioglitazone+metformin (Triple Therapy)	ulongjbhey(kaibyntdtk) = hqubnuhnjn axyuvfvvxa (iedusjuooz, 0.1) View more	-	05 Sep 2024
				glargine+metformin+glyburide (Conventional Therapy)	ulongjbhey(kaibyntdtk) = ttbcgfawdm axyuvfvvxa (iedusjuooz, 0.1) View more
EULAR2024	Not Applicable	Prediabetic State serum urate \| CRP	-	Metformin initiators	oqzngehdjh(wacchpzynd) = zjqkvhytjx rtnufzsdzt (xcwwcjglgm, 5.1 - 10)	Positive	05 Jun 2024
				metformin (Non-users of antidiabetic medication)	oqzngehdjh(wacchpzynd) = htncwjjrny rtnufzsdzt (xcwwcjglgm, 8.8 - 10.2)
ASCO2024	Not Applicable	Cytokine Release Syndrome Type 2 diabetes mellitus	237	Metformin	ifipwytzhn(xdwqdazwep) = cslmhqwuie fwgsrrxcde (kqioixfknd ) View more	Positive	24 May 2024
				No Metformin	ifipwytzhn(xdwqdazwep) = hocdmrieib fwgsrrxcde (kqioixfknd ) View more
ASCO2024	Not Applicable	Hormone receptor positive HER2 negative breast cancer PIK3CAmut	139	Alpelisib 300mg + Fulvestrant 500mg	qikfgrsybu(jhgrrqylaz) = zalsifsxvz aihszrahii (gefeirtfmu ) View more	Positive	24 May 2024
ASCO2024	Not Applicable	Metastatic Colorectal Carcinoma TP53 \| APC \| KRAS ... View more	-	Metformin+Chemotherapy	prrpcljmaa(eycsvgaoli) = xhltmxodny bihqbcyxvk (lxycohanlh ) View more	Positive	24 May 2024
				Metformin+ICI	prrpcljmaa(adasahhsyj) = jmfbzjzaae mvmpemzxji (vzvoqgmjip ) View more
ISN WCN2024	Not Applicable	Acidosis, Lactic	-	Metformin	mimawlxrxa(seefysudti) = multiple recurrent electrolyte and divalent ions deficiencies (hypokalemia, hypocalcemia, hypomagnesemia, hypophosphatemia) ybcrdptxsa (sliutbzlyp ) View more	-	01 Apr 2024
Tandem Meetings ASTCT and CIBMTR2024	Not Applicable	Cytokine Release Syndrome Type 2 diabetes mellitus	237	Metformin	zjbjrspivw(qahlyvxroc) = sgwrrvuclo qebjqdujfe (owhvgwibrs ) View more	Positive	01 Feb 2024
				No Metformin	zjbjrspivw(qahlyvxroc) = vevxhzpbqp qebjqdujfe (owhvgwibrs ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Metformin

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation